EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety following two or more years of vagus nerve stimulation (VNS Therapy) in pediatric patients with drug‐resistant epilepsy enrolled in a Russian VNS Registry

Anna A Feygina iD, Yana N Koshelyaevskaya, Maxine Dibué iD, Kira V Voronkova, Mikhail N Klochkov, Nadezhda Y Koroleva, Stanislav S Ivanov, Ekaterina S Bolshakova, Elza F Fatykhova

Brain and Behavior · 2023

DOI: 10.1002/brb3.3076 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Brain and Behavior, 2023. Verfasst von Anna A Feygina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs International, Neuromodulation, LivaNova PLC, London, UK. Hauptthemen laut MEDLINE: Vagus Nerve Stimulation, Drug Resistant Epilepsy, Epilepsy, Status Epilepticus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Following approval in 2009 of vagus nerve stimulation (VNS Therapy) for drug‐resistant epilepsy (DRE) in the Russian Federation, this is the first multicenter study across Russia to evaluate the safety and efficacy of adjunctive VNS Therapy.

Methods

The retrospective, observational registry included 58 pediatric patients with DRE (5–17 years old at implantation) who had ≥2 years of VNS. To ensure a robust evaluation process, changes in seizure frequency were evaluated for all seizure types as well as “most disabling” seizures (defined as seizures accompanied by falls, physical trauma, and/or incontinence in the absence of preventative measures).

Results

With 2 years of VNS Therapy, 37 of 49 patients (76%) experiencing the most disabling epileptic seizures had a >50% decrease in frequency of such seizures, and 16 (33%) reported no longer experiencing the “most disabling” seizure type. In addition, based on the McHugh Outcome scale, VNS Therapy had a positive outcome on both frequency and severity of all epileptic seizure types, with a >50% decrease in frequency of all epileptic seizure types noted in 37 of 58 patients (64%), and 31% of patients had a Class I outcome, including 11 patients (19%) who achieved seizure freedom. VNS Therapy also had a positive effect on the frequency of status epilepticus: 13 patients (22%) had status epilepticus prior to implantation with a mean rate of 9.4 ± 17.7 events per year (range, 0–52), and after VNS Therapy, only one patient continued to experience status epilepticus (at 1 event per 4–6 months). VNS Therapy had an acceptable safety profile and no adverse events leading to VNS discontinuation were reported.

Conclusions

The results demonstrate that VNS Therapy is being safely and effectively applied to pediatric patients in the Russian healthcare system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vagus Nerve StimulationDrug Resistant EpilepsyEpilepsyStatus EpilepticusHumansChildChild, PreschoolAdolescentRetrospective StudiesSeizuresRegistriesTreatment OutcomeVagus Nerve

Stichwörter der Autor:innen

RussiaVNS Therapydrug-resistant epilepsypediatric patientsseizure frequencyvagus nerve stimulation

Autor:innen und Institutionen

  • Medical Affairs International, Neuromodulation, LivaNova PLC, London, UK.
  • Department of Biostatistics, Regional United System of Medical Informatization, LLC, Moscow, Russia.
  • Faculty of Additional Professional Education, Pirogov Russian National Research Medical University, Moscow, Russia.
  • Neurology Department, Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russia.
  • Head of Center for Epileptology, Neurology, and Video-EEG monitoring, Bekhtereva Institute of the Human Brain, Russian Academy of Sciences, Saint Petersburg, Russia.
  • Neurosurgery Department, Republican Children's Clinical Hospital, Republic of Bashkortostan, Russia.

ORCID-Profile: Anna A Feygina, Maxine Dibué

Zitieren

APA

Feygina, A. A., Koshelyaevskaya, Y. N., Dibué, M., Voronkova, K. V., Klochkov, M. N., Koroleva, N. Y., Ivanov, S. S., Bolshakova, E. S., & Fatykhova, E. F. (2023). Efficacy and safety following two or more years of vagus nerve stimulation (VNS Therapy) in pediatric patients with drug‐resistant epilepsy enrolled in a Russian VNS Registry. Brain and Behavior. https://doi.org/10.1002/brb3.3076

Vancouver

Feygina AA, Koshelyaevskaya YN, Dibué M, Voronkova KV, Klochkov MN, Koroleva NY, et al. Efficacy and safety following two or more years of vagus nerve stimulation (VNS Therapy) in pediatric patients with drug‐resistant epilepsy enrolled in a Russian VNS Registry. Brain and Behavior. 2023. doi:10.1002/brb3.3076

BibTeX
@article{Feygina2023,
  author = {Feygina, Anna A and Koshelyaevskaya, Yana N and Dibué, Maxine and Voronkova, Kira V and Klochkov, Mikhail N and Koroleva, Nadezhda Y and Ivanov, Stanislav S and Bolshakova, Ekaterina S and Fatykhova, Elza F},
  title = {Efficacy and safety following two or more years of vagus nerve stimulation (VNS Therapy) in pediatric patients with drug‐resistant epilepsy enrolled in a Russian VNS Registry},
  journal = {Brain and Behavior},
  year = {2023},
  doi = {10.1002/brb3.3076}
}
Kostenlos starten →